Leslie Tari - Sep 11, 2023 Form 4 Insider Report for Cidara Therapeutics, Inc. (CDTX)

Role: CHIEF SCIENTIFIC OFFICER
Signature: /s/ Shane Ward, Attorney-in-Fact
Stock symbol: CDTX
Transactions as of: Sep 11, 2023
Transactions value $: -$17,509
Form type: 4
Date filed: 9/13/2023, 04:24 PM
Previous filing: Aug 14, 2023
Next filing: Mar 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CDTX	Common Stock	Sale	-$17.5K	-18.5K	-6.28%	$0.95	276K	Sep 11, 2023	Direct	F1, F2
holding	CDTX	Common Stock						1.48K	Sep 11, 2023	By spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9472 to $0.9692, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9472 to $0.9692, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.